PREDICTIVE VALUE OF MOLECULAR PARAMETERS IN PATIENTS WITH BASAL-LIKE TRIPL-NEGATIVE BREAST CANCER

Background: Pathological complete response is a predictor of favorable clinical outcome in patients with tripl-negative breast cancer. Over the last years there was an increasing interest to the search for predictive markers of tumor response to neoadjuvant chemotherapy (NACH). The purpose of the study is to assess predictive markers: cytokeratin 5/6, epidermal growth factor receptor (EGF1) and proliferation marker Ki-67 in patients with basal-like tripl-negative breast cancer.

Materials and methods: The study included 44 patients with basal-like tripl-negative breast cancer, who received 2–4 courses of NACH with FAC and CAX regimens. Estrogen and progesterone receptors, Her-2/neu, the levels of proliferative activity of Ki-67, CK 5/6 and EGFR1 were determined in all breast cancer biopsies. Response to NACH was assessed using RECIST scale.

Results. Pathological complete response was observed in 69 % of breast cancer patients, who had only EGFR1expression in tumor tissue (р=0.01). The best response was noted at high proliferative activity of tumor cells (90 %, р=0.0006) and when using CAX regimen (81 %, р=0.004). The model of logistic regression enables prediction of pathological complete response with high rates of sensitivity (82 %) and specificity (67 %).

Conclusion. The results obtained indicate that the studied markers can be used as predictors of clinical outcome and the devised model of logistic regression can be used to predict the chemotherapy response of breast cancer based on clinical pathological variables.

1. Brouckaert O., Wildiers H., Floris G., Neven P. Update on triple-negative breast cancer: prognosis and management strategies // Int. J. Womens Health. 2012. Vol. 12 (4). P. 511–520. doi: 10.2147/IJWH.S18541.

2. Carey L., Winer E., Viale G., Cameron D., Gianni L. Triple-negative breast cancer: disease entity or title of convenience? // Nat. Rev. Clin. Oncol. 2010. Vol. 10 (7). P. 1–10. doi: 10.1038/nrclinonc. 2010.154.

3. Chen X., Li J., Gray W.H., Lehmann B.D., Bauer J.A., Shyr Y., Pietenpol J.A. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer // Cancer Inform. 2012. Vol. 11. P. 147–156. doi: 10.4137/CIN.S9983.

4. Cheang M.C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K., Perou C.M., Nielsen T.O. Basal-like Breast Cancer defined by five biomarkers has superior prognostic value than Triple-negative phenotype // Clin. Cancer Res. 2008. Vol. 14 (5). P. 1368–1376. doi: 10.1158/1078-0432. CCR-07-1658.

5. Choo J.R., Nielsen T.O. Biomarkers for Basal-like Breast Cancer // Cancers. 2010. Vol. 2. P. 1040–1065. doi: 10.3390/cancers2021040.

6. De Ruijer T.C., Veeck J., De Hoom J.P., van Engeland M., TjanHeijnen V.C. Characteristics of triple-negative breast cancer // J. Cancer Res. Clin. Oncol. 2011. Vol. 137 (2). P. 183–192. doi: 10.1007/s00432- 010-0957-x

7. Dreyer G., Vandorpe T., Smeets A., Forceville K., Brouwers B., Neven P., Janssens H., Deraedt K., Moerman P., Van Calster B., Christiaens M.R., Paridaens R., Wildiers H. Triple-negative breast cancer; Clinical characteristics in the different histological subtypes // Breast. 2013. Vol. 22 (5). P. 761–766. doi: 10.1016/j.breast.2013.01.009.

8. Fasching P.A., Heusinger K., Haeberle L., Niklos M., Hein A., Bayer C.M., Rauh C., Schulz-Wendtland R., Bani M.R., Schrauder M., Kahmann L., Lux M.P., Strehl J.D., Hartmann A., Dimmler A., Beckmann M.W., Wachter D.L. Ki-67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment // BMC Cancer. 2011. Vol. 11. P. 486. doi: 10.1186/1471-2407-11-486.

9. Gluz O., Liedtke C., Gottschalk N., Pusztai L., Nitz U., Harbeck N. Triple-negative breast cancer – current status and future directions // Ann. Oncol. 2009. Vol. 20. P. 1913–1927. doi:10.1093/annonc/mdp492.

10. Hawk N., O`Regan R. Treatment of Triple-negative breast cancer // Com. Oncol. 2010. Vol. 7. P. 328–332.

11. Isakoff S.J. Triple-negative Breast Cancer: Role of Specific Chemotherapy Agents // Cancer J. 2010. Vol. 16 (1). P. 53–61. doi: 10.1097/ PPO.0b013e3181d24ff7.

12. Keam B., Im S-A., Lee K.-H., Han S.-W., Oh D-Y., Kim J. H., Lee S.-H., Han W., Kim D.-W., Kim T.-Y., Park I. A., Noh D.-Y., Heo D. S., Bang Y.-J. Ki-67 can be used for further classification of triple-negative breast cancer into two subtypes with different response and prognosis // Breast Cancer Res. 2011. Vol. 13. R2. P. 1–7. doi:10.1186/bcr2834.

13. Kreike B., van Kouwenhove M., Horlings H., Weigelt B., Peterse H., Bartelink H., van de Vijver M.J. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas // Breast Cancer Res. 2007. Vol. 9 (5). R. 65.

14. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., Pietenpol J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies // J. Clin. Invest. 2011. Vol. 121 (7). P. 2750–2767. doi: 10.1172/JCI45014.

15. Liedtke C., Mazouni C., Hess K.R., Sanders M. E., Chakravarthy A.B., Shyr Y., Pietenpol J.A. Response to Neoadjuvant therapy and Long-Term survival in patients with Triple-negative breast cancer // J. Clin. Onc. 2008. Vol. 28 (8). P. 1–18. doi:10.1172/JCI45014.

16. Masuda H., Masuda N., Kodama Y., Ogawa M., Karita M., Yamamura J., Tsukuda K., Doihara H., Miyoshi S., Mano M., Nakamori S., Tsujinaka T. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients // Cancer Chemother. Pharmacol. 2011. Vol. 67. P. 911–917. doi: 10.1007/ s00280-010-1371-4.

17. Montagna E., Maisonneuve P., Rotmensz N., Cancello G., Iorfida M., Balduzzi A., Galimberti V., Veronesi P., Luini A., Pruneri G., Bottiglieri L., Mastropasqua M. G., Goldhirsch A., Viale G., Colleoni M. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome // Clin. Breast Cancer. 2013. Vol. 13 (1). P. 31–39. doi: 10.1016/j. clbc.2012.09.002.

18. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., Hernandez-Boussard T., Livasy C., Cowan D., Dressler L., Akslen L.A., Ragaz J., Allen M.G., Gilks C.B., van de Rijn M., Perou C.M. Immunohistochemical and Clinical Characterization of the Basal-like Subtype of Invasive Breast Carcinoma // Clin. Cancer Res. 2004. Vol. 10. P. 5367–5374. doi: 10.1158/1078-0432.CCR-04-0220.

19. Perou C.M. Molecular Stratification of Tripl-negative Breast Cancer // The Oncologist. 2011. Vol. 16 (1). P. 61–70. doi: 10.1634/ theoncologist.2011-S1-61.

20. Rakha E.A., Elsheikh S.E., Aleksandarany M.A., Habashi H.O., Green A.R., Powe1 D.G., El-Sayed M.E., Benhasouna A., Brunet J.-S., Akslen L.A., Evans A.J., Blamey R., Reis-Filho J.S., Foulkes W.D., Ellis I.O. Triple-negative Breast Cancer: Distinguishing between Basal and Nonbasal subtypes // Clin. Cancer Res. 2009. Vol. 15 (7). P. 2302–2310. doi: 10.1158/1078-0432.CCR-08-2132.

21. Reis-Filho J.S., Tutt A.N. Triple-negative tumors: a critical review // Histopathology. 2008. Vol. 52 (1). P. 108–118. doi: 10.1111/j.1365-2559 .2007.02889.x.

22. Reis-Filho J.S., Milanezi F., Savage K., Savage K., Simpson P.T., Nesland J.M., Pereira E.M., Lakhani S.R., Schmitt F.C. Metaplastic breast carcinomas are basal-like tumors // Histopathology. 2006. Vol. 49. P. 10–21. doi: 10.1111/j.1365-2559.2006.02467.x.

23. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., Hess K.R., Stec J., Ayers M., Wagner P., Morandi P., Fan C., Rabiul I., Ross J.S., Hortobagyi1 G.N., Pusztail L. Breast cancer molecular sybtypes respond differently to preoperative chemotherapy // Clin. Cancer Res. 2005. Vol. 11 (16). P. 5678–5685. doi: 10.1158/1078-0432. CCR-04-2421.

24. Smith I.E. Neoadjuvant/presurgical treatment // Breast Cancer Res. 2008. 10 (Suppl. 4). S. 24. doi:10.1186/bcr2184.

25. Turner N., Tutt A., Ashworth A. Hallmarks of `BRCAness` in sporadic cancer // Nat. Rev. Cancer. 2004. Vol. 4. P. 814–819.